Impact of Baseline Anemia in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: A Prespecified Analysis From the VALIDATE‐SWEDEHEART Trial

Author:

Wester Axel1,Attar Rubina12,Mohammad Moman Aladdin1,Andell Pontus134,Hofmann Robin5,Jensen Jens67,Szummer Karolina34,Erlinge David1,Koul Sasha1

Affiliation:

1. Department of Cardiology Clinical Sciences Lund University Skåne University Hospital Lund Sweden

2. Department of Cardiology Clinical Medicine Aalborg University Aalborg Denmark

3. Unit of Cardiology Department of Medicine Karolinska Institute Stockholm Sweden

4. Heart and Vascular Division Karolinska University Hospital Stockholm Sweden

5. Division of Cardiology Department of Clinical Science and Education Södersjukhuset Karolinska Institute Stockholm Sweden

6. Department of Clinical Science and Education Södersjukhuset Karolinska Institute Stockholm Sweden

7. Unit of Cardiology Capio S:t Göran Hospital Stockholm Sweden

Abstract

Background The impact of baseline anemia in a contemporary acute coronary syndrome ( ACS ) population undergoing percutaneous coronary intervention in the era of predominant radial artery access, potent P2Y12 inhibition, and rare use of glycoprotein II b/ III a inhibitors has not been adequately studied. Methods and Results ACS patients who underwent percutaneous coronary intervention between 2014 and 2016 in the VALIDATESWEDEHEART (Bivalirudin Versus Heparin in ST ‐Segment and Non– ST ‐Segment Elevation Myocardial Infarction in Patients on Modern Antiplatelet Therapy in the Swedish Web System for Enhancement and Development of Evidence‐Based Care in Heart Disease Evaluated According to Recommended Therapies Registry) trial without missing values for hemoglobin were included (n=5482). Mortality, myocardial reinfarction, and major bleeding at 180 days were assessed using Cox regression models and propensity score matching. All studied comorbidities were more common in ACS patients who had anemia (n=792). ACS patients with anemia had higher rates of 180‐day mortality (6.9% versus 2.1%; hazard ratio, 1.9; 95% CI , 1.3–2.7; P <0.001), myocardial reinfarction (4.3% versus 1.9%; hazard ratio, 1.7; 95% CI , 1.1–2.7; P =0.013), and major bleeding (13.4% versus 8.2%; hazard ratio, 1.3; 95% CI , 1.0–1.6; P =0.041). The results were most evident in patients with a hemoglobin value <100 g/L, who had a nearly 10 times higher mortality rate. Conclusions Baseline anemia in ACS patients undergoing percutaneous coronary intervention, treated according to current practice including routine radial artery access, constitutes a high‐risk feature for both ischemic events, bleeding events, and mortality. A multidisciplinary approach is warranted to maximize benefit and minimize patient risk. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT02311231.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3